AZT overtaken

February 1998
Business News New Jersey;02/02/98, Vol. 11 Issue 5, p2
Reports on `Zerit,' an anti-Acquired Immune Deficiency Syndrome (AIDS) drug from Bristol-Myers Squibb. Outcome of sales for Zerit; Positive attributes of the drug.


Related Articles

  • Planned Excedrin launch gives Bristol-Myers Squibb headaches. Johnsen, Michael // Drug Store News;2/18/2002, Vol. 24 Issue 2, p27 

    Reports on the problems associated with the launching of a melt-in-your-mouth line extension of Excedrin analgesics manufactured by Bristol-Myers Squibb. Supply disruption related to one of the product's ingredients; Price range of the product.

  • BMS expands field force for Opdivo push. D. W. // Medical Marketing & Media;Mar2015, Vol. 50 Issue 3, p11 

    The article focuses on the financial performance of the pharmaceutical company Bristol-Myers Squibb Co. as well as its sales approach for the Opdivo drug for melanoma.

  • KAI, BMS Join Forces in $227M Heart Drug Deal.  // Bioworld Week;5/19/2008, Vol. 16 Issue 20, p3 

    The article reports that South San Francisco, California-based KAI Pharmaceuticals Inc. has collaborated with Bristol-Myers Squibb Co. (BMS) to develop and commercialize its heart drug KAI-9803. Under the partnership, BMS will pay KAI Pharmaceuticals an up-front payment of $25 million while KAI...

  • Novartis, BMS Withdraw IBS Drug from European Review.  // Chemical Market Reporter;6/11/2001, Vol. 259 Issue 24, p8 

    Reports on the decision of Novartis and Bristol-Myers Squibb Co. to withdraw their marketing application for the drug Zelmac from the European Agency for the Evaluation of Medicinal Products. Reason for the withdrawal; Forecast on the sales of Zelmac by 2005; Agreement between Novartis and...

  • ImClone/BMS/Merck Serono: Erbitux to fortify hold on the head and neck cancer market.  // PharmaWatch: Cancer;Nov2008, Vol. 7 Issue 11, p12 

    The authors reflect on the data presented by Bristol-Myers Squibb and ImClone Systems Inc. showing improved survival rate for head and neck cancer patients when receiving Erbitux and radiotherapy. They state that Erbitux was approved in the U.S. and European Union in 2006. They argue that...

  • COMPANY SPOTLIGHT- Bristol-Myers Squibb.  // PharmaWatch: CNS;Oct2006, Vol. 5 Issue 10, p22 

    The article presents the corporate profile of the pharmaceutical company, Bristol-Myers Squibb Co. in the U.S. The company is subdivided into sectors integrating to discover, develop and provide medicines catering to the medical needs of patients. The sectors include pharmaceuticals,...

  • POLITICAL ROUNDUP. Crawford, Tom // Georgia Trend;Sep2008, Vol. 24 Issue 1, p12 

    The article reports political updates in Georgia. Senator Tim Golden is giving a serious consideration for being a possible Democratic candidate for the governor position. Meanwhile, Attorney General Thurbert Baker has reached a settlement with Bristol-Myers Squibb Co. over charges of illegal...

  • Bms's Ability Gains FDA Nod. Krause, Carey // Chemical Market Reporter;11/25/2002, Vol. 262 Issue 19, p14 

    Reports that Bristol-Myers Squibb Co. has received approval from the U.S. Food and Drug Administration for its schizophrenia drug Abilify (aripiprazole). Bristol-Myers' partner in marketing Abilify in the U.S.; Competitors of the drug in the market; Analyst Carl Seiden's outlook for Abilify...

  • COMPANY SPOTLIGHT - Bristol-Myers Squibb.  // PharmaWatch: Monthly Review;Oct2008, Vol. 7 Issue 10, p26 

    The article presents the corporate profile of Bristol-Myers Squibb Co. (BMS), a personal care company which is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of pharmaceuticals and other heath care related products. Among its reportable business...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics